Publications: Joseph Kohles, Ph.D.

2011

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Blum JL, Kohles J, McKenna E, Scotto N, Hu S, Odom D, Kaye JA, Glück S. Breast Cancer Res Treat. 2011 Jan;125(2):431-9. Epub 2010 Nov 3.

Cost Comparison of Capecitabine in Patients With Breast Cancer. Rugo HS, Kohles J, Schulman KL Am J Clin Oncol. 2010 Jan 4.

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. Derman R, Kohles JD, Babbitt A. Clin Interv Aging. 2009;4:357-65. E-pub 2009 Oct 12.
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R J Womens Health (Larchmt). 2009 Jul;18(7):935-43.
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. Kolinsky K, Shen BQ, Zhang YE, Kohles J, Dugan U, Zioncheck TF, Heimbrook D, Packman K, Higgins B. Mol Cancer Ther. 2009 Jan;8(1):75-82.
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA. South Med J. 2009 May;102(5):486-92.

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis. Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Bone. 2008 Nov 12.
Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve population. Sebba AI, Broy S, Kohles JD, Weissman P.J Clin Densitom. 2008 Jul-Sep;11(3):417-23.
Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Gass ML, Kagan R, Kohles JD, Martens MG. Menopause. 2008 Jul-Aug;15(4 Pt 1):667-75.
Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates. Zaidi M, Epstein S, Harris ST, Kohles JD, Chesnut CH.Ann N Y Acad Sci. 2007 Nov;1117:273-82. Review.

"Economic burden of metastatic bone disease in the U.S." Schulman KL, Kohles J. Cancer. 2007 Jun 1;109(11):2334-42.
Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. Mortimer JE, Schulman K, Kohles JD. Clin Breast Cancer. 2007 Aug;7(9):682-9.
"Utility and Sensitivity of the Sore Throat Pain Model: Results of a Randomized Controlled Trial on the COX-2 Selective Inhibitor Valdecoxib." Schachtel BP, Pan S, Kohles JD, Sanner KM, Schachtel EP, Bey M. J Clin Pharmacol. 2007 May 24.

"Valdecoxib Provides Effective Pain Relief Following Acute Ankle Sprain" JA Diaz, C Cuervo, AM Valderrama, J Kohles J Int Med Res. 2006 Sep-Oct;34(5):456-67.

"Stability of Reconstituted Urokinase Solutions" Kohles, J.D.; Weld, M.; Asa'd, H.; Gunning, P.; Sterrett, J.R.; DeBari, V.A., Curr. Ther. Res. Clin. Exp. 2000, 61, 1-6.

"The Hololipoprotein Complex of b2Glycoprotein I and Dicaproyl Phosphatidylserine" Kohles, J.D.; Petersheim M.; DeBari V.A., Int J Clin Lab Res. 1999, 29, 117-121.
"Inhibition of b2Glycoprotein I Binding to Anionic Phospholipids" Kohles, J.D.; Petersheim M.; DeBari V.A., Drug Design & Discovery. 1999, 16(3), 227-236.
"Modification of b2Glycoprotein I by Glutardialdehyde. Conformational Changes and Aggregation Accompany Exposure of the Cryptic Epitope", Galazka, M.; Tang, M.; DeBari, V.A.; Kohles, J.D.; Lee, J.K.; Keil, L.B.; Petersheim, M., Biotechnol. Appl. Biochem., 1999, 76, 1-13.

"A Stable Multi-Subunit Complex of b2Glycoprotein I", Galazka, M.; Keil, L.B.; Kohles, J.D.; Li, J.; Kelty, S.P.; Petersheim, M.; DeBari, V.A., Thrombosis Research, 1998, 90, 131-137.
"Phospholipid-independent binding of beta 2glycoprotein I by IgA from patients with antiphospholipid syndrome." Galazka M.W.; Keil L.B.; Kohles J.D.; Petersheim M.; DeBari V.A., Ann Clin Lab Sci, 1998, 28, 153-159.